The Osiris Advantage

The technology being developed by Osiris Therapeutics, Inc. has shown significant advantages to other cellular therapies in development for the following reasons:

Availability – Over ten thousand treatments can be produced from a single donation.
Universal Compatibility – Products can be used in any patient without typing or matching.
Ease of Use – Treatment can be accomplished with a simple I.V. infusion or injection.
Intellectual Property - The Company has 47 issued U.S. patents, each having one or more foreign counterparts.

Stem Cell Availability

Osiris Therapeutics has distinguished itself from other companies and research institutions through manufacturing methods that allow rapid growth in a controlled fashion to produce billions of stem cells from a single donation. Once produced, the cells can be stored in a frozen state, ready to be used when they are needed.

The feasibility of manufacturing very large numbers of MSCs in a controlled and regulated manner is a critical part of the Osiris plan. We have combined insights into cell production with a strategy for treating many patients with a single donation of MSCs. Assuming success in our product development and regulatory affairs, this approach should offer patients access to the stem cell treatments in a timely, cost effective manner.

Universal Compatibility

In both animal and human clinical studies, Osiris scientists and academic researchers have found that MSCs are generally not rejected by the host immune system. This unique feature eliminates the need to tailor MSCs based on donor matching and means that patients can forgo the harmful side effects of immune suppression.

Mesenchymal stem cells are different from blood, organs, and other stem cells. MSCs grown in culture from a single donor can be used to treat many patients. Because of the absence of rejection, these MSCs allow for the development of treatments applicable to all patients - a “universal” therapy.

Most other approaches to cell therapy depend on matching or amplifying the patient’s own cells. In contrast, MSCs offer the opportunity to treat patients in the acute setting, potentially within hours of the onset of symptoms. For example, a patient with an acute heart attack could be treated upon arrival at the emergency room, rather than waiting as individually customized cells are prepared over weeks or months, as is the case with other cell technologies.

Ease of Use

As part of the normal healing process, the body’s native MSCs residing in one’s bone marrow are attracted to sites of tissue damage. Osiris has harnessed this natural homing ability in its therapeutic MSCs such that they can be infused via standard intravenous or injection methods to treat conditions in various damaged areas of the body. For most applications, Osiris' MSCs are delivered to the hospital in a standard IV bag that hospital staff are familiar with using, so that adoption of new techniques or preparation methods should be minimized if and when our product candidates are commercially available.

Intellectual Property

Osiris has established a significant patent position in adult stem cell technology. The Company has committed to protect its intellectual property position and currently owns or has exclusive license to 47 issued U.S. patents. Foreign counterparts to these patents, including important composition of matter claims, have been filed.

The Osiris Advantage

Stem Cell Availability

Universal Compatibility

Ease of Use

Intellectual Property

Proprietary immune privileged technology: